<DOC>
	<DOCNO>NCT02254265</DOCNO>
	<brief_summary>This Phase 2/3 study evaluate safety efficacy 2 different dose concentration OTX-101 dose twice day eye 84 day compare placebo ( vehicle ) patient keratoconjunctivitis sicca ( dry eye disease ) .</brief_summary>
	<brief_title>Phase 2/3 Dose-Ranging Study Safety Efficacy OTX-101 Treatment Keratoconjunctivitis Sicca</brief_title>
	<detailed_description>Keratoconjunctivitis sicca ( KCS ) common multifactorial ophthalmologic disorder tear ocular surface characterize symptom burn , sting , itch , grittiness , scratchiness , foreign body sensation , dryness , stickiness tire eye sensation . This study first clinical safety efficacy study OTX-101 design compare two dose concentration OTX-101 vehicle ( placebo ) reduce sign symptom KCS evaluate safety dose twice day eye 84 day period .</detailed_description>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Subjects age 18 year old date inform consent . 2 . All subject must provide sign write consent prior participation studyrelated procedure . 3 . Patientreported history KCS period least 6 month . 4 . Clinical diagnosis bilateral KCS support OTX1012014001 study assessment . 5 . Lissamine green conjunctival stain sum score ≥ 3 ≤ 9 total possible score 12 ( score excludes superior zone 2 4 ) eye Screening Baseline . 6 . Global symptom score ≥ 40 Screening Baseline . 7 . Corrected Snellen VA well 20/200 eye . 8 . Willing discontinue use current dry eye therapy ( include artificial tear ocular lubricant ) study runin period . 9 . Female subject childbearing potential must negative urine pregnancy test Screening . Women childbearing potential ( ie , woman either postmenopausal one year surgically sterile ) must use acceptable form contraception throughout study . 1 . Use cyclosporine ophthalmic emulsion 0.05 % ( Restasis® ) within 3 month prior Screening . 2 . Previous treatment failure ( lack efficacy ) cyclosporine ophthalmic emulsion 0.05 % ( Restasis ) . 3 . Diagnosed Sjögren 's disease ˃5 year prior Screening . 4 . Clinical diagnosis seasonal perennial allergic conjunctivitis . 5 . Use systemic topical medication know cause dry eye within 7 day prior Screening throughout study period . These include follow medication : Immunomodulators ( permit dose stable 3 month prior screen change study period ) Antihistamines ( include overthe counter ( OTC ) ) Cholinergics Antimuscarinics Tricyclic antidepressant Phenothiazines Retinoids 6 . Oral omega3 fatty acid ( permit dose stable 3 month prior Screening change study period ) 7 . Use topical ophthalmic medication , prescription ( include antiglaucoma medication ) OTC ( include artificial tear ) , assign study medication study period . 8 . Current active eye disease KCS ( i.e. , disease topical systemic ophthalmic medication necessary ) . 9 . History herpes keratitis . 10 . Unstable macular disease ( e.g. , agerelated macular degeneration , diabetic maculopathy ) . Stable macular disease define reduction central VA within 6 month prior Screening . 11 . Diagnosis chronic uveitis . 12 . Corneal transplant ( e.g. , penetrate keratoplasty , lamellar keratoplasty , Descemet 's strip endothelial keratoplasty ( DSEK ) ) . 13 . Corneal refractive surgery ( e.g. , laserassisted situ keratomileusis ( LASIK ] ) photo refractive keratectomy ( PRK ) , limbal relaxing incision ( LRI ) ) within 6 month prior screen postoperative refractive surgery symptom dryness resolve . 14 . Cataract surgery within 3 month prior Screening . 15 . Nonlaser glaucoma surgery time ; glaucoma laser procedure within 3 month prior Screening . 16 . Presence punctal plug past history permanent punctal occlusion ( e.g. , cautery ) . 17 . Lagophthalmos clinically significant eyelid margin irregularity study eye whether congenital acquire . 18 . Presence conjunctivochalasis ( i.e. , mechanical blockage lower lid punctum redundant conjunctiva ) . 19 . Presence pterygium study eye . 20 . Unwilling discontinue use contact lenses duration study . 21 . Preplanned elective surgery hospitalization study period . 22 . HIVpositive . 23 . Unable reliably report symptom history . 24 . Has know hypersensitivity contraindication study medication ( ) component . 25 . Has history presence chronic generalize systemic disease Investigator feel might increase risk subject confound result ( ) study . 26 . Has severe/serious ocular condition , unstable medical condition , Investigator 's opinion , may preclude study treatment followup . 27 . Women pregnant breastfeeding . 28 . Participation drug device clinical investigation within 30 day prior entry study and/or period study participation . 29 . Previous randomization study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>